To read the full story, subscribe or sign in.

Following in-depth therapeutic review, Mogrify adds $17M to series A

May 4, 2021

LONDON – Cell transdifferentiation specialist Mogrify Ltd. has raised $17 million in the second close its series A, taking the round to $33 million and enabling the company to progress three cell therapy programs to the clinic.

BioWorld Financings Cell therapy Series A

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Single dose of Pfizer vaccine not strong enough against variants, U.K. study shows

BioWorld

LONDON – A single dose of Pfizer Inc./Biontech SE’s COVID-19 vaccine does not promote a strong enough immune response to provide protection against variants of...

Today's news in brief

BioWorld

BioWorld briefs for May 10.

Next up, Novavax, after April’s vaccine woes and therapeutic failures

BioWorld

Dangerous blood clots and thrombocytopenia, rare simultaneous side effects seen with two adenoviral vector vaccines from Astrazeneca plc and Johnson & Johnson, as...

Split vote at adcom for avacopan; FDA not Hy on Chemocentryx trial setup

BioWorld

The FDA’s Arthritis Advisory Committee panelists groped through cloudy data while complaining about the design of the phase III trial for Chemocentryx Inc.’s...